



# FDA Approval Decisions Report November-January 2008

**Jeremy Zhou**  
Senior Analyst  
415-782-0454, x158  
jzhou@reveredata.com

**Daniel Grundig**  
Analyst  
415-782-0454, x176  
dgrundig@reveredata.com

## Overview

For investors in pharmaceutical and biotech companies, rigorous monitoring of drug pipelines is essential. No milestone is more influential than the FDA approval decision date, frequently called the PDUFA date (from Prescription Drug User Fee Act).

This Revere Report features **companies with expected FDA approval decision dates in the next three months**. To provide further insights into **each drug candidate's likelihood of approval and competitive landscape**, the FDA Approval Decisions Report includes **key data based on Revere's patented classification system and proprietary pipeline database** - specifically, whether each drug candidate:

- utilizes a mechanism of action already approved by the FDA in other drugs
- faces two or fewer alternative drugs with the same mechanism of action for the same indication
- would be the first or second FDA approved drug for the company

## Contents

- Recent Approval Results/Updates
- Expected PDUFA Dates in the Next Three Months
- Price and Financial Info

---

Copyright 2007 by Revere Data, LLC. All rights reserved.

### Notes:

1. Some expected PDUFA (Prescription Drug User Fee Act) dates are Revere estimates based on NDA (New Drug Approval) submission dates. Companies are not obligated to disclose NDA submission dates or PDUFA dates, and the FDA may change its approval decision date without prior notice.
2. Drugs developed by private firms or by companies not traded publicly in the U.S. are excluded from this analysis.

### Disclaimer:

Revere Data is an independent provider of investment research and information and does not offer broker / dealer, money management, hedge fund management, investment advisory, or investment banking services.

The information contained in this report is based on a limited analysis of qualitative, statistical, and financial data and should not be interpreted as recommendations based on a complete investment evaluation. The information is based on sources that Revere Data believes to be reliable, but no representation, express or implied, is made with respect to the accuracy, completeness, reliability, or timeliness. The information is subject to change without notice, and Revere Data does not accept responsibility to update it.

Revere Data does not accept responsibility or liability for any direct, indirect, special, consequential, or other losses or damages of any kind whatsoever arising out of access to, or use of, this report or any information contained in it.

**For more information on Revere's independent research data and investment analytics, please contact us as follows:**

**Revere Data, LLC** | 60 East 42nd St. Suite 716 | New York, NY 110165  
866.REVERE9 (866.738.3739) | sales@reveredata.com | www.reveredata.com

## Recent Approval Results/Updates

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Previous Expected PDUFA Date	Approval results/update
<b>DepoMed, Inc. (DEPO) / Glumetza (Metformin GR)</b>				
	Once Daily Formulation For The Treatment Of Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes	Biguanides	10/02/2007	Result Pending
<b>Biovail Corporation (USA) (BVF) / Glumetza (Metformin GR)</b>				
	Once Daily Formulation For The Treatment Of Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes	Biguanides	10/02/2007	Result Pending
<b>Bristol Myers Squibb Co. (BMY) / Abilify (Aripiprazole)/Abilify Discmelt (Aripiprazole Orally Disintegrating Tablet)</b>				
	Treatment Of Schizophrenia In Pediatric Patients 13-17 Years Old	Serotonin/Dopamine Receptor Partial Agonists	10/05/2007	Result Pending
<b>ImClone Systems Incorporated (IMCL) / Erbitux (Cetuximab)</b>				
	Third-Line Treatment Of Metastatic Colorectal Cancer (Colon Cancer) After Failure Of Both Irinotecan- And Oxaliplatin-Based Regimens	Monoclonal Antibodies	10/08/2007	<b>Approved</b> 10/03/2007
<b>Bristol Myers Squibb Co. (BMY) / Erbitux (Cetuximab)</b>				
	Third-Line Treatment Of Metastatic Colorectal Cancer (Colon Cancer) After Failure Of Both Irinotecan- And Oxaliplatin-Based Regimens	Monoclonal Antibodies	10/08/2007	<b>Approved</b> 10/03/2007
<b>Theravance, Inc. (THR) / Telavancin</b>				
	Complicated Skin And Soft Tissue Infections Caused By Gram-Positive Bacteria (cSSTIs)	Glycopeptides	10/08/2007	<b>Approvable Letter Received</b> 10/22/2007
<b>GlaxoSmithKline plc (ADR) (GSK) / Hycamtin Oral (Topotecan Hydrochloride)</b>				
	Relapsed Small Cell Lung Cancer (SCLC)	Topoisomerase I Inhibitors	10/12/2007	<b>Approved</b> 10/15/2007
<b>Johnson &amp; Johnson (JNJ) / Doribax (Doripenem)</b>				
	Complicated Intra-Abdominal Infection, Complicated Urinary Tract Infection	Carbapenems	10/15/2007	<b>Approved</b> 10/15/2007
<b>Biogen Idec Inc. (BIIB) / Tysabri (Natalizumab)</b>				
	Moderately To Severely Active Crohn's Disease	Alpha 4 Integrin Inhibitors	10/15/2007	<b>Rescheduled to</b> 01/11/2008
<b>Elan Corporation, plc (ADR) (ELN) / Tysabri (Natalizumab)</b>				
	Moderately To Severely Active Crohn's Disease	Alpha 4 Integrin Inhibitors	10/15/2007	<b>Rescheduled to</b> 01/11/2008
<b>Merck &amp; Co., Inc. (MRK) / Januvia (Sitagliptin Phosphate)</b>				
	Adjunct To Diet And Exercise, And As Add-On Therapy To A Sulfonylurea In Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes, Add-On Therapy To The Combination Of A Sulfonylurea Plus Metformin In Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes	Dipeptidyl Peptidase (DPP) Inhibitors	10/15/2007	<b>Approved</b> 10/17/2007
<b>Merck &amp; Co., Inc. (MRK) / Januvia (Sitagliptin Phosphate)</b>				

Company (Symbol) / Drug Candidate			
Adjunct To Diet And Exercise, And In Combination With Metformin To Improve Glycemic Control In Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes	Dipeptidyl Peptidase (DPP) Inhibitors	10/15/2007	<b>Approved</b> 10/17/2007
Novartis AG (ADR) (NVS) / Tasigna (Nilotinib)			
Chronic Myeloid Leukemia (CML)/Acute Lymphoblastic Leukemia (ALL) Resistant To Gleevec	Tyrosine Kinase Inhibitors	<u>10/16/2007</u>	<b>Approved</b> 10/29/2007
Merck & Co., Inc. (MRK) / Isentress (Raltegravir)			
Human Immunodeficiency Virus (HIV-1) Infection In Adults Who Have Evidence Of Viral Replication And Are Resistant To Multiple Antiretroviral Agents	Integrase Inhibitors, Integrase inhibitors	10/17/2007	<b>Approved</b> 10/12/2007
ZymoGenetics, Inc. (ZGEN) / rThrombin			
Reduce Bleeding During Surgery/Critical Care (Hemostat)	Coagulating Agents (Coagulants)	<u>10/18/2007</u>	<b>Rescheduled to</b> 01/17/2008
Bristol Myers Squibb Co. (BMY) / Ixempra (Ixabepilone)			
Monotherapy To Treat Patients With Metastatic Or Locally Advanced Breast Cancer After Failure Of Chemotherapies	Antimicrotubule Agents	10/19/2007	<b>Approved</b> 10/16/2007
Genzyme Corporation (GENZ) / Renvela (Sevelamer Carbonate)			
Reduction Of Serum Phosphorus In Patients With Chronic Kidney Disease On Dialysis	Phosphate Binding Agents	10/19/2007	<b>Approved</b> 10/22/2007
Genentech, Inc. (DNA) / Herceptin (Trastuzumab)			
In Combination With Taxotere As First-Line Treatment Of HER-2 Positive Metastatic Breast Cancer	Monoclonal Antibodies	10/19/2007	Result Pending
Roche Holding Ltd. (ADR) (RHHBY) / Herceptin (Trastuzumab)			
In Combination With Taxotere As First-Line Treatment Of HER-2 Positive Metastatic Breast Cancer	Monoclonal Antibodies	10/19/2007	Result Pending
Cardiome Pharma Corp.(USA) (CRME) / RSD1235 I.V. (Vernakalant)			
Acute Conversion Of Atrial Fibrillation	Sodium Channel Blocking Agents/Potassium Channel Blocking Agents	<u>10/19/2007</u>	<b>Rescheduled to</b> 01/18/2008
DOR BioPharma, Inc. (DORB) / orBec (Oral Beclomethasone Dipropionate)			
Acute Gastrointestinal Graft-Versus-Host Disease (GVHD)	Steroidal Anti-Inflammatory Drugs (SAID)	<u>10/19/2007</u>	<b>Non-Approvable Letter Received</b> 10/19/2007
Solvay S.A. (ADR) (SVYSY) / Solvay Pharmaceuticals Tedisamil (Intravenous Potassium Channel Blocker)			
Atrial Fibrillation, Atrial Flutter	Potassium Channel Blocking Agents	<u>10/19/2007</u>	<b>Rescheduled to</b> 01/18/2008
Noven Pharmaceuticals, Inc. (NOVN) / Stavzor (Valproic Acid Softgel)			
Migraine	Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors	<u>10/22/2007</u>	<b>Approvable Letter Received</b> 10/23/2007
Noven Pharmaceuticals, Inc. (NOVN) / Stavzor (Valproic Acid Softgel)			
Epilepsy	Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors	<u>10/22/2007</u>	<b>Approvable Letter Received</b> 10/23/2007
Noven Pharmaceuticals, Inc. (NOVN) / Stavzor (Valproic Acid Softgel)			

Company (Symbol) / Drug Candidate			
Bipolar Disorder	Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors	<u>10/22/2007</u>	<b>Approvable Letter Received</b> 10/23/2007
Adams Respiratory Therapeutics, Inc. (ARXT) / Mucinex With Codeine (Guaifenesin/Codeine Combination Extended-Release)			
Cough Associated With The Common Cold, Expectorants Inhaled Irritants, And Stable Bronchitis		<u>10/26/2007</u>	<b>Approvable Letter Received</b> 10/29/2007
sanofi-aventis (ADR) (SNY) / Taxotere (Docetaxel)			
Induction Therapy Of Locally Advanced Head And Neck Cancer Prior To Chemoradiotherapy And Surgery	Antimicrotubule Agents	10/26/2007	<b>Approved</b> 10/01/2007

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases.


## Expected PDUFA Dates in the Next Three Months

### November Drug Candidates

#### Companies

BioMarin Pharmaceutical Inc. (BMRN)  
 Bristol Myers Squibb Co. (BMY)  
 Forest Laboratories, Inc. (FRX)  
 Fresenius Medical Care AG & Co. (ADR) (FMS)  
 GlaxoSmithKline plc (ADR) (GSK)  
 Impax Laboratories Inc. (IPXL)  
 Mylan Inc. (MYL)  
 Regeneron Pharmaceuticals, Inc. (REGN)  
 Sciele Pharma Inc. (SCRX)  
 SkyePharma PLC (ADR) (SKYEY)  
 sanofi-aventis (ADR) (SNY)

#### Sectors

**I** Biopharmaceuticals  

 Cardiovascular System  
 Endocrinology/Metabolism  
 Hematology  
 Immunology  
 Infectious Diseases  
 Neurology

#### Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [ ].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 <sup>st</sup> /2 <sup>nd</sup> Drug?
<b>Mylan Inc. (MYL) / Nebivolol</b>						
	Hypertension	Beta Adrenergic Receptor Blocking Agents (Beta Blockers)	11/01/2007	Yes	<b>No</b> Multiple Drugs	No
<b>Forest Laboratories, Inc. (FRX) / Bertek Nebivolol</b>						
	Hypertension	Beta Adrenergic Receptor Blocking Agents (Beta Blockers)	11/01/2007	Yes	<b>No</b> Multiple Drugs	No
<b>GlaxoSmithKline plc (ADR) (GSK) / Variza (Gepirone ER)</b>						
	Major Depression Disorder	Serotonin Receptor Agonists	<u>11/02/2007</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>sanofi-aventis (ADR) (SNY) / Pentacel</b>						
	Combination Vaccine For Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenzae type b (Hib) In Children	Bacterial/Viral	<u>11/02/2007</u>	Yes	<b>Yes</b> Infanrix HeXa-HepB-IPV/Hib / (GSK)	No
<b>SkyePharma PLC (ADR) (SKYEY) / Controlled Release Sular (Nisoldipine)</b>						
	Hypertension	Calcium Channel Blocking Agents	<u>11/02/2007</u>	Yes	<b>No</b> Multiple Drugs	No
<b>Sciele Pharma Inc. (SCRX) / Controlled Release Sular (Nisoldipine)</b>						
	Hypertension	Calcium Channel Blocking Agents	<u>11/02/2007</u>	Yes	<b>No</b> Multiple Drugs	No
<b>Impax Laboratories Inc. (IPXL) / Impax Pharmaceuticals Vadova (Carbidopa/Levodopa)</b>						
	Idiopathic Parkinson's Disease, Post-Encephalitic Parkinsonism, Symptomatic Parkinsonism	Dopamine Receptor Agonists	11/16/2007	Yes	<b>Yes</b> Lodosyn (Carbidopa) / (BMY) Sinemet/Sinemet CR (Carbidopa/Levodopa) / (BMY)	Yes
<b>Bristol Myers Squibb Co. (BMY) / Abilify (Aripiprazole)/Abilify Discmelt (Aripiprazole Orally Disintegrating Tablet)</b>						
	Major Depressive Disorder (MAD) In Adults As Adjunctive To Antidepressant Therapy	Serotonin/Dopamine Receptor Partial Agonists	11/16/2007	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>BioMarin Pharmaceutical Inc. (BMRN) / Kuvan (Sapropterin Dihydrochloride)/FormerlyPhenoptin</b>						

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 <sup>st</sup> /2 <sup>nd</sup> Drug?
<b>Company (Symbol) / Drug Candidate</b>						
	Phenylketonuria (PKU)	Enzyme Cofactors	<u>11/23/2007</u>	No	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Fresenius Medical Care AG &amp; Co. (ADR) (FMS) / PhosLo (Calcium Acetate)</b>						
	Hyperphosphatemia In Stage 4 Chronic Kidney Disease Patients	Phosphate Binding Agents	11/23/2007	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	Yes
<b>Regeneron Pharmaceuticals, Inc. (REGN) / Riloncept (Interleukin-1 Cytokine Trap)</b>						
	CIAS1-Associated Periodic Syndrome (CAPS)	Interleukin-1 Receptor Antagonists (IL-1 Antagonists)	11/30/2007	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	Yes




Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1<sup>st</sup>/2<sup>nd</sup> Drug** -- 1st or 2nd FDA Approved Drug of the Company?

## December Drug Candidates

### Companies

Bayer AG (ADR) (BAYRY)  
 DOV Pharmaceutical, Inc. (DOVP)  
 Jazz Pharmaceuticals, Inc. (JAZZ)  
 Ligand Pharmaceuticals Inc. (LGND)  
 Neurocrine Biosciences, Inc. (NBIX)  
 Onyx Pharmaceuticals, Inc. (ONXX)  
 Pharmacyclics, Inc. (PCYC)  
 Solvay S.A. (ADR) (SVYSY)  
 Wyeth (WYE)

### Sectors

**I** Biopharmaceuticals  
 Musculoskeletal System  
 Neurology  
 Oncology

#### Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [ ].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 <sup>st</sup> /2 <sup>nd</sup> Drug?
<b>Ligand Pharmaceuticals Inc. (LGND) / Viviant (Bazedoxifene)</b>						
	Prevention Of Postmenopausal Osteoporosis	Selective Estrogen Receptor Modulators (SERM)	December 2007	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	Yes
<b>Wyeth (WYE) / Viviant (Bazedoxifene)</b>						
	Prevention Of Postmenopausal Osteoporosis	Selective Estrogen Receptor Modulators (SERM)	December 2007	Yes	<b>No</b> Multiple Drugs	No
<b>Neurocrine Biosciences, Inc. (NBIX) / Indiplon Immediate Release Capsule</b>						
	Primary (Chronic) And Transient Insomnia	Gamma-Aminobutyric Acid (GABA) Receptor Agonists	<u>12/12/2007</u>	Yes	<b>No</b> Multiple Drugs	Yes
<b>DOV Pharmaceutical, Inc. (DOVP) / Indiplon Immediate Release Capsule</b>						
	Primary (Chronic) And Transient Insomnia	Gamma-Aminobutyric Acid (GABA) Receptor Agonists	<u>12/12/2007</u>	Yes	<b>No</b> Multiple Drugs	Yes
<b>Solvay S.A. (ADR) (SVYSY) / Solvay Pharmaceuticals Luvox CR (Fluvoxamine Controlled Release)</b>						
	Obsessive Compulsive Disorder (OCD) And Social Anxiety Disorder (SAD)	Selective Serotonin Reuptake Inhibitors (SSRI)	<u>12/21/2007</u>	Yes	<b>No</b> Multiple Drugs	No
<b>Jazz Pharmaceuticals, Inc. (JAZZ) / Luvox CR (Fluvoxamine Controlled Release)</b>						
	Obsessive Compulsive Disorder (OCD) And Social Anxiety Disorder (SAD)	Selective Serotonin Reuptake Inhibitors (SSRI)	<u>12/21/2007</u>	Yes	<b>No</b> Multiple Drugs	No
<b>Onyx Pharmaceuticals, Inc. (ONXX) / Nexavar (Sorafenib)</b>						
	Hepatocellular Carcinoma (Liver Cancer)	Raf Kinase Inhibitors/Vascular Endothelial Growth Factor Receptor Inhibitors (VEGFR)	12/26/2007	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	Yes
<b>Bayer AG (ADR) (BAYRY) / Nexavar (Sorafenib)</b>						
	Hepatocellular Carcinoma (Liver Cancer)	Raf Kinase Inhibitors/Vascular Endothelial Growth Factor Receptor Inhibitors (VEGFR)	12/26/2007	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Pharmacyclics, Inc. (PCYC) / XCYTRIN (Motexafin Gadolinium)</b>						
	Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases	Chemo/Radiation Sensitizer	<u>12/31/2007</u>	No	<b>Yes</b> Only Candidate with This PMOA for This Indication	Yes

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? 1<sup>st</sup>/2<sup>nd</sup> Drug -- 1st or 2nd FDA Approved Drug of the Company?

## January Drug Candidates

### Companies

Biogen Idec Inc. (BIIB)  
 Cardiome Pharma Corp.(USA) (CRME)  
 Elan Corporation, plc (ADR) (ELN)  
 GlaxoSmithKline plc (ADR) (GSK)  
 Johnson & Johnson (JNJ)  
 MiddleBrook Pharmaceuticals, Inc. (MBRK)  
 Omrix Biopharmaceuticals, Inc. (OMRI)  
 Progenics Pharmaceuticals, Inc. (PGNX)  
 Roche Holding Ltd. (ADR) (RHHBY)  
 Solvay S.A. (ADR) (SVYSY)  
 Spectrum Pharmaceuticals, Inc. (SPPI)  
 Wyeth (WYE)  
 ZymoGenetics, Inc. (ZGEN)

### Sectors

- I Biopharmaceuticals
  - Cardiovascular System
  - Digestive System
  - Immunology
  - Infectious Diseases
  - Oncology
  - Surgery
- I Medical Devices
  - General Surgery

#### Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [ ].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 <sup>st</sup> /2 <sup>nd</sup> Drug?
<b>Omrix Biopharmaceuticals, Inc. (OMRI) / Evicel (Liquid Fibrin Sealant)</b>						
	Fibrin Sealant For Hemostasis (Bleeding Control) During Kidney Surgery And General Surgical Procedures	Topical	01/08/2008	Yes	<b>No</b> Multiple Drugs	No
<b>Spectrum Pharmaceuticals, Inc. (SPPI) / ISO-vorin (Levofolinic Acid)</b>						
	Osteosarcoma (Bone Cancer)	Folic Acid Derivatives	<u>01/11/2008</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	Yes
<b>Biogen Idec Inc. (BIIB) / Tysabri (Natalizumab)</b>						
	Moderately To Severely Active Crohn's Disease	Alpha 4 Integrin Inhibitors	<u>01/11/2008</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Elan Corporation, plc (ADR) (ELN) / Tysabri (Natalizumab)</b>						
	Moderately To Severely Active Crohn's Disease	Alpha 4 Integrin Inhibitors	<u>01/11/2008</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>ZymoGenetics, Inc. (ZGEN) / rThrombin</b>						
	Reduce Bleeding During Surgery/Critical Care (Hemostat)	Coagulating Agents (Coagulants)	<u>01/17/2008</u>	Yes	<b>Yes</b> Evithrom (Human Thrombin) / (OMRI) Thrombin JMI / (KG)	Yes
<b>Cardiome Pharma Corp.(USA) (CRME) / RSD1235 I.V. (Vernakalant)</b>						
	Acute Conversion Of Atrial Fibrillation	Sodium Channel Blocking Agents/Potassium Channel Blocking Agents	<u>01/18/2008</u>	Yes	<b>Yes</b> Lanoxin (Digoxin) / (GSK)	Yes
<b>Solvay S.A. (ADR) (SVYSY) / Solvay Pharmaceuticals Tedisamil (Intravenous Potassium Channel Blocker)</b>						
	Atrial Fibrillation, Atrial Flutter	Potassium Channel Blocking Agents	<u>01/18/2008</u>	Yes	<b>Yes</b> Azimilide / (PG) Tikosyn (Dofetilide) / (PFE)	No
<b>Johnson &amp; Johnson (JNJ) / Tibotec TMC125 (Etravirine)</b>						
	Treatment Of HIV-1 Infection In Combination With Other Antiretroviral Agents	Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)	<u>01/18/2008</u>	No	<b>Yes</b> Sustiva (Efavirenz) / (BMY) Rescriptor (Delavirdine Mesylate) / (PFE)	No
<b>MiddleBrook Pharmaceuticals, Inc. (MBRK) / Amoxicillin PULSYS</b>						

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 <sup>st</sup> /2 <sup>nd</sup> Drug?
	Acute Pharyngitis/Tonsillitis (Strep Throat) In Adults And Adolescents Due To Group A Streptococcal Infections	Penicillin Derivatives	<u>01/23/2008</u>	Yes	<b>Yes</b> Amoxil (Amoxicillin) / (GSK)	No
<b>Roche Holding Ltd. (ADR) (RHHBY) / Xeloda (Capecitabine)</b>						
	First-Line Or Second-Line Treatment Of Metastatic Colorectal Cancer (Colon Cancer) In Combination With Eloxatin (Oxaliplatin) And With Or Without Avastin (Bevacizumab)	Pyrimidine Analogs	01/25/2008	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>GlaxoSmithKline plc (ADR) (GSK) / Cervarix (HPV16/HPV18 Vaccine)</b>						
	Human Papillomavirus (HPV) Vaccine, Cervical Cancer Vaccine	Papillomavirus, Papillomavirus Vaccines	01/29/2008	Yes	<b>Yes</b> Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine) / (MRK)	No
<b>Progenics Pharmaceuticals, Inc. (PGNX) / MNTX (Subcutaneous Methylnaltrexone)</b>						
	Opioid-Induced Constipation (OIC) In Patients Receiving Palliative Care	Opioid Receptor Antagonists	<u>01/30/2008</u>	No	<b>Yes</b> Entereg (Alvimopan) / (ADLR)	Yes
<b>Wyeth (WYE) / MNTX (Subcutaneous Methylnaltrexone)</b>						
	Opioid-Induced Constipation (OIC) In Patients Receiving Palliative Care	Opioid Receptor Antagonists	<u>01/30/2008</u>	No	<b>Yes</b> Entereg (Alvimopan) / (ADLR)	No

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1<sup>st</sup>/2<sup>nd</sup> Drug** -- 1st or 2nd FDA Approved Drug of the Company?

## Price and Financial Info

### November 2007

Data as of 11/01/2007

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
BioMarin Pharmaceutical Inc.	BMRN	27.31	2,620.617	1,587,545	19.15	340.98	589.0	73.84%	70.43%
Bristol Myers Squibb Co.	BMJ	29.59	58,544.140	11,157,402	12.48	54.94	3,582.0	20.19%	16.77%
Forest Laboratories, Inc.	FRX	38.97	12,320.367	3,452,192	n/a	n/a	n/a	-19.28%	-22.70%
Fresenius Medical Care AG & Co. (ADR)	FMS	52.23	15,272.359	76,965	n/a	91	237.9	17.74%	14.33%
GlaxoSmithKline plc (ADR)	GSK	51.26	142,375.567	1,572,766	13.25	69.63	6,510.4	-3.25%	-6.66%
Impax Laboratories Inc.	IPXL	10.50	614.090	146,880	10.47	125.32	89.6	50.00%	46.59%
Mylan Inc.	MYL	15.21	3,784.274	3,342,023	4.91	112.15	1,490.4	-25.51%	-28.93%
Regeneron Pharmaceuticals, Inc.	REGN	20.70	1,367.410	667,592	7.62	111.52	460.7	4.07%	0.66%
sanofi-aventis (ADR)	SNY	43.56	118,433.939	1,565,986	n/a	n/a	n/a	2.66%	-0.75%
Sciele Pharma Inc.	SCRX	24.21	864.323	1,049,219	691.46	76.59	204.2	12.76%	9.35%
SkyePharma PLC (ADR)	SKYEY	3.10	252.646	n/a	n/a	1,434.57	47.0	-29.22%	-32.64%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,

### December 2007

Data as of 11/01/2007

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Bayer AG (ADR)	BAYRY	82.27	62,882.406	n/a	n/a	84.39	4,596.4	61.79%	58.38%
DOV Pharmaceutical, Inc.	DOVP	0.24	26.581	67,401	1.63	0	14.7	-27.27%	-30.69%
Jazz Pharmaceuticals, Inc.	JAZZ	13.09	321.367	33,608	7.46	54.66	148.0	n/a	
Ligand Pharmaceuticals Inc.	LGND	5.17	523.756	489,537	11.24	6.97	115.4	-52.44%	-55.85%
Neurocrine Biosciences, Inc.	NBIX	9.49	360.524	701,426	1.34	19.03	147.3	-14.96%	-18.38%
Onyx Pharmaceuticals, Inc.	ONXX	47.37	2,591.335	988,354	6.17	9.53	454.4	158.85%	155.44%
Pharmacyclics, Inc.	PCYC	2.15	55.832	68,978	1.73	0	32.3	-58.65%	-62.07%
Solvay S.A. (ADR)	SVYSY	149.80	12,688.229	n/a	3.57	43.96	613.3	13.48%	10.07%
Wyeth	WYE	48.01	64,556.212	6,794,888	n/a	n/a	n/a	-4.76%	-8.17%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,

### January 2008

Data as of 11/01/2007

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Biogen Idec Inc.	BIIB	73.57	21,583.180	5,651,010	16.69	31.25	671.3	54.01%	50.60%
Cardiome Pharma Corp.(USA)	CRME	10.41	661.227	326,832	6.47	0	100.2	-8.36%	-11.78%
Elan Corporation, plc (ADR)	ELN	23.81	11,130.832	3,177,116	n/a	0	805.9	65.58%	62.16%
GlaxoSmithKline plc (ADR)	GSK	51.26	142,375.567	1,572,766	13.25	69.63	6,510.4	-3.25%	-6.66%
Johnson & Johnson	JNJ	64.94	187,969.487	10,125,748	n/a	n/a	n/a	-3.33%	-6.75%
MiddleBrook Pharmaceuticals, Inc.	MBRK	1.41	65.779	107,246	13.95	44.4	12.2	-65.36%	-68.77%
Omxix Biopharmaceuticals, Inc.	OMRI	33.02	559.473	200,933	5.10	0.72	83.7	65.18%	61.77%
Progenics Pharmaceuticals, Inc.	PGNX	22.75	613.486	234,296	5.68	0	111.0	-9.58%	-12.99%

Roche Holding Ltd. (ADR)	RHHBY	84.65	146,031.837	n/a	5.70	17.99	19,832.0	-3.75%	-7.16%
Solvay S.A. (ADR)	SVYSY	149.80	12,688.229	n/a	3.57	43.96	613.3	13.48%	10.07%
Spectrum Pharmaceuticals, Inc.	SPPI	3.90	121.237	190,599	1.87	0	71.0	-29.35%	-32.76%
Wyeth	WYE	48.01	64,556.212	6,794,888	n/a	n/a	n/a	-4.76%	-8.17%
ZymoGenetics, Inc.	ZGEN	13.28	909.720	362,424	6.20	45.75	198.5	-16.11%	-19.52%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,